Proteasome Activity Restricts Lentiviral Gene Transfer into Hematopoietic Stem Cells and is Down-Regulated by Cytokines that Enhance Transduction

Francesca Romana Santoni de Sio1,2, Paolo Cascio3, Anna Zingale1, Mauro Gasparini4,5 and Luigi Naldini1,2*

1San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET) and 2San Raffaele Vita Salute University, San Raffaele Scientific Institute, via Olgettina 58, 20132, Milano, Italy; 3Department of Morphophysiology, School of Veterinary Medicine, University of Turin, Grugliasco, Torino, Italy; 4Politecnico di Torino, Torino and 5University Center for Statistics in the Biomedical Sciences, San Raffaele Vita-Salute University, Milano, Italy

*To whom correspondence should be addressed:
Luigi Naldini, M.D., Ph.D., San Raffaele Telethon Institute for Gene Therapy, Via Olgettina, 58, 20132 Milano. Tel: +39-02-2643-4681 Fax: -4668 naldini.luigi@hsr.it

Running title: Proteasome Restricts Lentiviral Vectors in HSC

Scientific Heading: Gene Therapy

Word counts: 5001

Cells were obtained from human cord blood, after informed consent according to the Declaration of Helsinki.

This research was supported by grants from Telethon (TIGET), NIH (2 P01 HL053750-11 CFDA No. 93.839), EU (QLK3-1999-00859 and CONSERT) to L.N., and the Italian Ministry of Scientific Research to L.N. and M.G.
ABSTRACT

The therapeutic potential of hematopoietic stem cell (HSC) gene therapy can be fully exploited only by reaching efficient gene transfer into HSCs without compromising their biological properties. Although HSCs can be transduced by HIV-derived lentiviral vectors (LVs) in short \textit{ex vivo} culture, they display low permissivity to the vector, requiring cytokine stimulation to reach high-frequency transduction. Using stringent assays of competitive xenograft repopulation, we show that early-acting cytokines synergistically enhanced human HSC gene transfer by LV without impairing engraftment and repopulation capacity. Using S-phase suicide assays, we show that transduction enhancement by cytokines was not dependent on cell cycle progression and that LVs can transduce quiescent HSCs. Pharmacological inhibition of the proteasome during transduction dramatically enhanced HSC gene transfer, allowing reaching very high levels of vector integration in their progeny \textit{in vivo}. Thus, LVs are effectively restricted at a post-entry step by the activity of this proteolytic complex. Unexpectedly, cytokine stimulation rapidly and substantially down-regulated proteasome activity in hematopoietic progenitors, highlighting one mechanism by which cytokines may enhance permissiveness to LV gene transfer. These findings demonstrate that antiviral responses ultimately mediated by proteasomes strongly limit the efficiency of HSC transduction by LVs, and establish improved conditions for HSC-based gene therapy.
INTRODUCTION

Hematopoietic stem cells (HSCs) are attractive targets for the cell and gene therapy of several inherited and acquired diseases. Because of self-renewing ability, multipotency and clonogenic potential, they can reconstitute all hematopoietic lineages in a transplanted host. Upon ex vivo gene transfer, they may generate a progeny of gene-corrected cells potentially for a life-span. For gene therapy to be efficacious, however, effective gene transfer must be reached into HSCs without inducing detrimental effects on their biological properties.

The vectors most often used for HSC gene transfer are gamma-retroviral vectors (RVs). More recently, HIV-derived lentiviral vectors (LVs) have been proposed as improved tools for this task. Both RVs and LVs integrate into the genome of host cells, but, while RV integration is dependent on target cell mitosis, LVs transduce both proliferating and non-proliferating cells. Since HSCs are considered to be mostly quiescent cells, they require stimulation with cytokines that trigger them into the cell cycle, in order to be transduced by RVs. Consequently, all the protocols developed for RV-mediated HSC gene transfer involve prolonged ex vivo manipulation and/or induction of cell cycle entry and proliferation, conditions that in most cases were shown to decrease the frequency of HSCs in the culture, and compromise their long term repopulating ability. Nevertheless, recent clinical trials have demonstrated that RVs can be successfully used for HSC-based SCID gene therapy. However, the in vivo selective growth advantage of transduced cells, which enabled amplification of a small input of transduced HSCs, was a key factor in the success of these trials. To broaden significantly the scope of HSC-based gene therapy, preservation and transduction of the majority of HSCs harvested for a transplant would be required.

Others and we have shown efficient transduction of CB (CB) NOD/SCID mouse-Repopulating Cells (SRCs), considered to be closely related to HSCs, after a short incubation with LV, in the absence of cytokine stimulation. Surprisingly, and in apparent contrast with the lack of LV requirement for target cell proliferation, we later found a significant enhancement in gene transfer in the presence of a combination of early-acting cytokines (Interleukin 6 - IL6, Stem Cell
Factor - SCF, Thrombopoietin - TPO and Flt3 Ligand - Flt3L$^{16}$, previously shown to induce moderate ex vivo SRC expansion$^{17}$. It remained to be established whether the gain in gene transfer could be offset, even for a short cytokine exposure, by a decreased engraftment or long-term repopulation capacity of the transduced cells. In order to address these issues in the SRC model, stringent experimental approaches are needed.

LVs have been shown to be restricted in quiescent T lymphocytes, which must exit from G$_0$, and presumably progress to the G$_{1b}$ phase of the cell cycle, in order to be infected by HIV-1, or transduced by LVs$^{18-21}$. The transduction block in quiescent cells may be due to the lack of required cellular co-factors, and/or the expression of restrictive factors$^{22}$. Several recent works have revealed that mammalian cells have developed defense mechanisms against retroviral infection (reviewed in Goff$^{23}$). Some of these factors may affect viral uncoating, reverse transcription, and/or target the internalized viral particles to degradation by the ubiquitin-proteasome pathway, whose antiviral activity was observed in earlier studies of HIV-infected lymphocytes$^{24}$.

In this work, we assessed the impact of early-acting cytokines on HSCs in stringent models of NOD/SCID mouse repopulation, investigated factors limiting the efficiency of LV gene transfer in HSCs, and developed new strategies that may effectively overcome them.
METHODS

Cells

HeLa, 293T and K562 cells were maintained in IMDM, U937 cells in RPMI-1640 (SIGMA), both containing 10% fetal bovine serum (FBS; Invitrogen). CD34+ cells were obtained from human CB, as described, after informed consent according to the Declaration of Helsinki and the H. San Raffaele Bioethical Committee, and used fresh or after freezing.

Transduction

Vector stocks were prepared, concentrated and titered as described. Transfer vectors were: pRRLsin.cPPT.hPGK.eGFP.Wpre, pRRLsin.cPPT.hPGK.YFP.Wpre and pCCLsin.cPPT.hPGK.eGFP.Wpre; packaging plasmids were: pCMVΔR8.74 or pMDLg/pRRE, pRSV-Rev and pMD2.VSV-G. 5x10⁵-1x10⁶ CD34+ cells/ml were incubated with 10⁸, unless otherwise indicated, LV Transducing Units (TU)/ml, for 18-24 hr in serum-free medium (StemSpan – StemCell Technologies), with or without: recombinant-human (rh) IL6 (20 ng/ml), SCF (100 ng/ml), Flt3L (100 ng/ml), TPO (20 ng/ml) (Peprotech), tested individually or in combination. 10⁵ HeLa or 293T/ml, 10⁶ U937/ml, and 2x10⁵ K562/ml were transduced for 12 hours with 5x10⁴, 2x10⁵ and 5x10⁵ LV TU/ml, respectively. Proteasome inhibitors MG132 (Calbiochem) and PS-341 (Millennium) were added to the transduction medium at the indicated concentration. Transduced cells were analysed by FACS (FACSCalibur) 6-14 days after transduction and by quantitative real-time PCR (qPCR) after 3 weeks; qPCR primers and probe complementary to the GFP or ψ vector sequences, and conditions were as described; primers and probe complementary to the human TERT gene were used to normalize DNA content. CFC assays were performed as described, and colonies scored by light and fluorescence microscopy at day 10-14.
**NOD/SCID transplant**

NOD/LtSz scid/scid (NOD/SCID) mice obtained from the British Columbia Cancer Research Center or Charles River (Calco) were handled as described according to protocols approved by the H. San Raffaele Animal Care and Use Committee (IACUC 244) and communicated to the Ministry of Health and local authorities. Each non-competitively repopulated (reference) mouse received 4x10⁵ CD34+ cells transduced with or without cytokines with either LV-GFP or LV-YFP; each competitively repopulated mouse received 2x10⁵ CD34+ cells transduced with LV-GFP (or LV-YFP) in the presence of cytokines and 2x10⁵ CD34+ cells transduced with LV-YFP (or LV-GFP) without cytokines. In S-phase suicide assays, transduced CD34+ cells were injected together with 5x10⁵ CD34-negative accessory cells. Six-ten weeks after transplant, bone marrow (BM) cells were retrieved and plated in CFC assays, as described. For FACS analysis, the following human-specific Cy5-phycoerythrin- (for the competitive repopulation assays) or phycoerythrin- (for other assays) conjugated antibodies were used: anti-hCD45, anti-hCD34, anti-hCD19, anti-hCD13, and IgG1 isotype control (DAKO). Cells were stained with 2 μg/ml PI and the percentage of antibody-positive/transgene-positive cells was determined after excluding PI-positive, nonviable cells. PI was not used in combination with Cy5 phycoerythrin-conjugated antibodies and YFP, because of emission wavelength overlapping. Mice were considered engrafted if hCD45+ cells exceeded 1% of total BM cells. For qPCR, genomic DNA was extracted from BM-derived cells and analyzed using primers and probe complementary to the vector RRE sequence (fw 5’ TGAGGGCTATTGAGGCGC3’ 600 nM; rv 5’ TGCCTGGAGCTGCTTGATG 3’ 600 nM; probe 5’ 6-FAM-TTGCAACTCACGTCCTCTG-MGB 3’ 200 nM), to the human TERT gene (fw 200 nM; rv 600 nM; probe 200 nM) and to the murine β-actin gene (fw: 5’ AGAGGGAAATCGTGCGTGAC 3’ 300 nM; rv 5’ CAATAGTGACCTGGCCGT 3’ 750 nM; probe 5’ VIC-CACTGCGCATCCTTTCCCTTCC-MGB 3’ 200 nM); qPCR conditions were as described. LV copy numbers were normalized to human DNA content. Percentage of human...
engraftment was calculated as ratio between human and total (human+murine) DNA. Samples were analyzed using Abi Prism 7900 HT (Applied Biosystems).

**S-phase suicide assay**

After transduction with or without cytokines, $5 \times 10^5$ CD34+ cells/ml were exposed to $2 \times 10^6$M cytosine 1-β-D-arabinofuranoside (Ara-C; SIGMA) for 12 hours, or left untreated, then washed twice and plated in liquid culture and CFC assays. Killing efficiency was assessed by scoring CFC numbers.

**Cell cycle analysis**

CD34+ cells were incubated in DNA staining buffer (PBS 1% saponin with 300KU RNAse and 50 μg/ml PI), for 10 minutes in ice and then analyzed by FACS. Cell aggregates and dead cells were eliminated from further analysis by gating individual cells in the FL3-area versus FL3-width plot.

**Proteasome assays**

Cellular extracts were prepared as described with minor modifications. Briefly, cells were sonicated in ice-cold buffer (50mM Tris/HCl pH 7.5, 1mM DTT, 0.25M sucrose, 5mM MgCl2, 0.5mM EDTA, 2mM ATP) and extracts were prepared by centrifugation. Peptidase activities were assayed by monitoring production of 7-amino-4-methylcoumarin (amc) from fluorogenic peptides, as described. Suc-LLVY-amc (for chymotrypsin-like activity), Boc-LRR-amc (for trypsin-like activity) and Ac-YVAD-amc (for caspase-like activity) were used at 100 μM in 20 mM Tris-HCl pH 7.5, 1 mM ATP, 2 mM MgCl2, 0.1% BSA. Fluorescence of released amc (excitation, 380 nm; emission, 460 nm) was monitored continuously at 37°C, following addition of cellular extracts, by a Carry Eclipse spectrofluorimeter. Background activity was determined in the presence of proteasome inhibitors MG132 (for chymotrypsin and caspase-like activities; 10μM) and β-lactone (for trypsin-like activity; 20μM). Assays were calibrated using standard solutions of free
fluorophores. Substrate consumption at the end of the reaction never exceeded 1%. Concentration of dimethyl sulfoxide never exceeded 0.7%.

Statistical analysis
The Wilcoxon signed rank test was used for comparison between paired samples; the Wilcoxon-Mann-Whitney rank sum test for comparison between two independent samples; the Kruskal-Wallis test, a nonparametric analogue of the ANOVA test, for comparison between more than two independent samples. Calculations were done using the function \texttt{wilcox.test}, native to the free software \texttt{R}. For the data in Figure 3e, in order to make the differences in %GFP comparable across different doses, a logarithmic transformation was applied. A standard sign test was used for the data in Figure 5. For the analysis of the Competitive Repopulation Assay see Supplementary Table 1 and accompanying text.
RESULTS

Cytokine stimulation preserved NOD/SCID repopulating ability of human HSCs

To stringently assess repopulation capacity of CB SRCs after a short ex vivo culture with and without a combination of early-acting cytokines (SCF, TPO, IL6, Flt3L), we performed competitive NOD/SCID repopulation assays. We transduced CB CD34+ cells in both culture conditions with either of two self-inactivating LVs differing only for the transgene (GFP or YFP). We injected half cells transduced with cytokines by LV-YFP and half cells transduced without cytokines by LV-GFP into the same NOD/SCID mouse (YFP+/GFP– group, n=12). To avoid any transgene-specific effect we swapped transgene and culture condition in a parallel group of mice (YFP–/GFP+ cyt group, n=8). In parallel, we transplanted mice with the same total number of the same cells transduced in only one culture condition, and with either of the two vectors (reference, non-competitively repopulated groups: GFP+ cyt, GFP– cyt, YFP+ cyt, YFP– cyt, n=4,6,5,5, respectively).

Aliquots of the transduced cells were kept in culture and plated in colony-forming cell (CFC) assays for assessing transduction. Analysis of suspension cultures and CFC assay showed a higher transduction level when cytokines were used for both vectors (data not shown). Ten weeks after the transplant, we analyzed NOD/SCID BM. Representative FACS plots of the three-channel analysis are shown in Figure 1. Transgene expression was assessed both in the total human CD45+ cell population, and, in order to verify transduction of multi-potent HSCs, in the progenitor, lymphoid and myeloid fractions (Figure 1b,c). All repopulated mice (40 out of 44 assayed; numbers of mice per group refer to the successfully repopulated mice) showed multi-lineage engraftment by transduced SRCs.

As shown in Table 1, human cells engrafted mice at variable levels, as expected for the NOD/SCID model. The engraftment level was slightly lower in competitively than in non-competitively repopulated mice (21% versus 35% CD45+ cells on average, respectively, n=20,20).

The frequency of transgene-expressing cells was on average higher for SRCs transduced with cytokines, in all permutations of vector type and experimental condition tested.
To assess whether cytokine stimulation had an impact on the repopulating capacity of the transduced SRCs we developed a statistical model (Supplementary Table 1). We confirmed that cytokines had a significant effect (p-value = 0.011) on the frequency of transgene-positive cells, with an estimated positive effect in the logodd scale equal to +1.044. This means that if the mean frequency of transduction is for example 30% for unstimulated cells (-cyt), the estimated mean frequency increases to 55% when stimulated (+cyt).

Because the interaction between the parameters “cytokines” and “xenotransplant model” (competitive or not) was not significant (p-value = 0.77), we concluded that cytokine stimulation had a positive significant impact on SRC transduction without changing significantly its extent and direction between reference and competitively repopulated mice, thus showing that cytokine-stimulated SRCs had an engraftment capacity similar to that of unstimulated cells. We confirmed our findings at the vector DNA level, performing PCR analysis on DNA extracted from human colonies derived from engrafted mice BM (Supplementary Figure 1).

Overall, these results showed that cytokine treatment, while increasing LV transduction of human HSCs, did not affect their engraftment and repopulating ability in a stringent xenotransplant model.

Cytokine enhancement of SRC gene transfer does not require cell cycle progression

A possible explanation for the cytokine enhancement of LV transduction was that only the SRCs in the G1 phase of the cell cycle were susceptible to transduction, and that cytokines enhanced transduction triggering the exit of SRCs from G0. Progression into late G1, however, commits the cells to DNA replication and mitosis, and may thus impair the long-term repopulating ability of HSCs, a difficult feature to assess in the NOD/SCID model. Since we could not measure the cell cycle status of the few SRCs contained in the CD34+ population, we performed an S-phase suicide assay on the transduced cells.
We stimulated or not CB-derived CD34+ cells with cytokines, and then exposed the cells or not to 1-β-D-arabinofuranoside (Ara-C) to kill cycling cells. Ara-C was previously reported to effectively kill hematopoietic stem/progenitor cells (HSPCs) passing through S-phase. To verify the cell cycle status of the cells after treatment, we stained them with propidium iodide and analyzed by FACS (Figure 2a). Cytokines increased the fraction of cells in S-phase (17% for +cyt vs 9% for –cyt) and this difference was completely abrogated when the cells were exposed to Ara-C.

We then transduced CD34+ cells with LV-GFP, exposed them or not to Ara-C, performed in vitro assays, and injected the cells into NOD/SCID mice. CFC assay showed that Ara-C killed the majority of cytokine-stimulated cells and a much smaller fraction of non-stimulated cells, indicating that cytokines triggered committed progenitors into S-phase, as expected. Nevertheless, when scoring transduction frequency in the surviving cultures, both suspension cultures and CFCs, we did not observed a decrease in transduction levels in the cells exposed to Ara-C (Figure 2b,c). We obtained similar results using ³H-Thymidine as killing agent (not shown).

For transplantation, transduced cells were matched for number of viable cells prior to Ara-C treatment, and injected with CD34Neg accessory cells. NOD/SCID BM cells were harvested 6-8 weeks after transplant, analyzed by FACS and plated for CFC assay (Table 2). FACS analysis showed, for the cells not exposed to Ara-C, a higher SRCs transduction level when cytokines were added (91% vs 54% for +cyt vs –cyt). Interestingly, we observed a similarly significant difference in the cells exposed to Ara-C (61% vs 29% for +cyt Ara-C and –cyt Ara-C, respectively). CFC assay confirmed these data.

Since cytokine enhancement of SRC transduction was not abrogated by killing proliferating cells, it did not require progression into the S-phase of the cell cycle. Ara-C treatment decreased engraftment and transduction levels in both stimulated and non-stimulated SRCs, indicating that a fraction of SRCs were sensitive to Ara-C, most likely because they were induced to proliferate early after transplant. One can thus postulate that the quiescent SRC fraction was mainly responsible for
repopulating the mice transplanted with Ara-C exposed cells; because these cells were transduced to substantial levels, these data strongly suggest that LVs are able to transduce quiescent SRCs ex vivo.

Lentiviral gene transfer is restricted by proteasome in HSPCs

We showed that cytokines enhancement of LV gene transfer was not dependent on the envelope pseudotype (Supplementary Figure 2), indicating that cytokine stimulation did not affect a specific entry pathway. Thus, we evaluated factors influencing the post-entry steps of viral infection. Because of its emerging effector role in many cellular response pathways, we assessed the influence of proteasome on LV transduction of HSPCs. In a first set of experiments we transduced CD34+ cells with the standard dose of LV-GFP, with or without cytokine stimulation, and added different doses of the reversible peptide-aldehyde proteasome inhibitor MG132 during the transduction period. After transduction cells were washed in order to remove the inhibitor, and kept in suspension culture. After two weeks, FACS analysis revealed a substantial MG132 dose-dependent increase in the frequency of GFP-expressing cells and in their Mean Fluorescence Intensity (MFI), both for the stimulated and not stimulated cells (Figure 3a,b). Remarkably, at high concentrations of MG132, we were able to transduce virtually all the stimulated cells, and to very high MFI, and up to 90% of the non-stimulated cells. We were not able to further increase the transduction level in non-stimulated cells without reaching toxic doses of MG132. To verify that the observed enhancement of transduction was specifically dependent on proteasome inhibition, we repeated these experiments using the more powerful peptide-boronate inhibitor PS-341 and obtained similar results (Figure 3c,d).

In a second set of experiments we evaluated the effect of a constant concentration of MG132 (1 μM) on CD34+ cells transduced with or without cytokines and different LV amounts. The same number of cells were transduced with or without MG132, cultured, and plated in CFC assay to test the toxicity of MG132 on HSPCs. Proteasome inhibitor substantially enhanced transduction at each
vector dose, both for cytokine stimulated and not stimulated cells, whether assayed in suspension cultures or by CFC (Figure 3e) (p=0.008 and p=0.016 for MG132 treated vs. untreated cells, in +cyt and –cyt conditions, respectively, both for suspension culture cells and CFC). Stimulated cells showed higher toxicity in response to the inhibitor than non-stimulated cells. This could be due, however, to the extremely high GFP expression level and vector integration load, as indicated by the increasing percentage of CFC death with increasing LV dose (Figure 3e and data not shown).

In order to confirm at the molecular level the enhancement of transduction by proteasome inhibitor, we performed quantitative real time PCR (qPCR) analysis on the transduced progenitors DNA. We used two primers-probe systems to amplify different vector sequences and found that both proteasome inhibitors (PS341 and MG132) increased from three- to seven-fold the average vector copy number per cell, both in non-stimulated and stimulated cells. The enhancement was dependent on the inhibitor dose, reaching an average of 14 and 61 copies per cell in non-stimulated and stimulated cells, respectively, at the highest doses of vector and inhibitor (Figure 3f).

Overall, these data indicated that the proteasome effectively restricted LV gene transfer in HSPCs.

Cytokines down-regulate the proteasome activity of HSPCs

We assessed the contribution of individual cytokines to the observed enhancement of LV transduction by taking advantage of the response amplification mediated by MG132. We transduced CD34+ cells with or without 1 μM MG132 and in the absence or presence of IL6, SCF, TPO and Flt3L, tested separately or in combination (Figure 4). Each cytokine induced only a modest increase in gene transfer as compared to the unstimulated cells, both when scored in liquid culture and in CFC assay. However, addition of MG132 during transduction revealed a higher response of the cells stimulated with a single cytokine than that seen in non-stimulated cells. When comparing cells stimulated with each individual cytokine with cells stimulated by their combination, the effect of
cytokines on gene transfer appeared to be synergistic, as indicated by the frequency of transduction, which reached saturation at 100%, and by the transduced cells MFI.

We then assayed the proteasomal chymotriptic-, tryptic- and caspase-like activities in CD34+ cells stimulated or not with cytokines. We found that, for all activities tested, cytokine-stimulated CD34+ cells displayed a significantly lower specific activity, on average 60%, compared to not stimulated cells (global p-value= 2x10^-18) (Figure 5a). We then performed a time-course analysis of the chymotriptic-like proteasome activity, which accounts for 90% of the total activity of this complex, of CD34+ cells stimulated or not with cytokines (Figure 5b). Whereas the proteasome activity progressively increased in cultured unstimulated CD34+ cells, it was rapidly and strongly down-regulated by exposure to cytokines. Indeed, the difference in specific activity between stimulated and not stimulated cells was higher at 6 hrs (earliest time analyzed; 30% of unstimulated cells) than at 24 hours.

Since we observed an additive effect of cytokines and proteasome inhibitor in enhancing transduction (see Fig. 3 and 4), we measured the proteasome activity 24 hours after either treatment, or their combination (Figure 5c). MG132 down-regulated the proteasome activity more effectively than the cytokines, and the combination was slightly but not significantly more effective than the drug alone.

Finally, we assessed the contribution of each individual cytokine (Figure 5d). We observed a moderate down-regulation of proteasome activity when CD34+ cells were exposed to SCF, TPO or Flt3L, while no effect was seen with IL6. No cytokine tested alone reached the effect of the cocktail, indicating an additive effect of three cytokines.

Overall, the rapid onset and the substantial extent of proteasome activity down-regulation induced by cytokines in HSPCs indicate a likely role of this response in mediating the enhancement of LV transduction. However, because the addition of cytokines to cells exposed to proteasome inhibitor further enhanced transduction without likely inducing a comparatively stronger
proteasome activity down-regulation, it is conceivable that other pathways activated by cytokines beside their effect on the proteasome contribute to the increased permissiveness to LV transduction.

Proteasome restriction of LV appears to be a specific feature of HSPCs

In order to verify if proteasome restriction of LVs was common to different cell types, we evaluated the effect of MG132 on the transduction of different cell lines, either of hematopoietic origin (K562 and U937) or not (293T and HeLa). Cells were transduced with a constant LV-GFP dose and with increasing MG132 doses, washed and analyzed two weeks later by FACS. The effect of MG132 on transduction was much lower for all the cell lines tested than that observed in HSPCs (Figure 6a,b; compare with Figure 3a,b). To exclude the possibility that proteasome inhibitor was not effective because the level of transduction for some cell lines had already reached saturation without the drug, we repeated the experiments using lower doses of vector and obtained similar results (data not shown). We then assayed the proteasome chymotriptic-like activity in all cell types tested. The activity in all cell line extracts was about one third to one forth of that found in HSPC, stimulated or not with cytokines, respectively (Figure 6c).

These results suggest that proteasome restriction of LV is a specific feature of HSPCs and that it could be due to the high proteasome activity observed in these cells.

Proteasome inhibition strongly enhances SRC gene transfer by LV

We then verified the effect of proteasome inhibition on SRC transduction. We transduced CD34+ cells stimulated or not with cytokines with 2x10^7 TU/ml of LV-GFP and with or without 0.7μM MG132, performed in vitro assays, and transplanted them into NOD/SCID mice. We chose a lower vector dose than that used in previous NOD/SCID experiments to better detect drug-dependent enhancement of transduction. We analyzed NOD/SCID BM by FACS and qPCR. FACS analysis showed increasingly higher transduction levels comparing unstimulated cells to unstimulated plus MG132 cells to stimulated cells. However, we reached such a high frequency of transduction in the
latter condition that any possible further enhancement by MG132 addition could not be detected (Figure 7a). Thus, we used qPCR specific for LV sequence and for human DNA to evaluate the number of integrated vector copies per human cell and the level of human engraftment per mouse (Figure 7b,c). Proteasome inhibitor increased the average vector copy number by 2-fold in unstimulated cells and 1.5-fold in stimulated cells, reaching the remarkable number of 34 copies per human cell in the graft (highest score) and an average of 23 in SRCs transduced with cytokines and inhibitor. It should be highlighted that, consistently with the results shown before, cytokine treatment alone increased 3-fold the vector copy number per cell. The differences between the four groups were statistically significant (p-value=0.002).

Importantly, we did not observe a detrimental effect of MG132 on the SRC repopulating ability. In fact, we obtained similar engraftment levels in all groups tested (p-value= 0.46). Furthermore, when we analyzed the mouse BM by FACS, we observed multilineage engraftment by transduced cells in all the groups (Figure 7d).

These results prove that proteasome effectively restricts LV in SRCs and highlight a new strategy to overcome the low permissiveness of human HSC to LV gene transfer.
DISCUSSION

Using a stringent assay of competitive xenograft repopulation, we show that human CB HSCs, transduced to high efficiency by a short exposure to LV in presence of SCF, TPO, IL6 and Flt3L, maintain comparable repopulation capacity as cells transduced in the absence of stimulation. Both types of cells contributed similarly to the multi-lineage human graft, and yielded similar numbers of progenitors. The enhancement of LV gene transfer was dependent on the synergy of all four cytokines.

Our marking studies provides rigorous, and until now lacking, proof that early-acting cytokines, which are currently investigated for ex vivo HSC expansion, do not impair stem cell properties in the conditions tested. Previous studies reported a decreased homing capacity of CB CFCs after exposure to some of the cytokines used in this study\textsuperscript{40}. Although our results do not suggest such impairment, we cannot exclude that cytokine-stimulated cells may compensate a decreased homing capacity with a higher in vivo self-renewal and/or clonogenicity. Clonal analysis of the human graft in the repopulated mice will help clarifying these issues. On the other hand, because the SRC assay does not provide extended long-term follow-up and does not support T-lymphopoiesis, we cannot exclude detrimental effects of the cytokines on these more-difficult-to-assess stem cell features. Further studies in new xenograft models\textsuperscript{41-44}, or, more likely, the follow-up of patients treated with LV-mediated HSC gene therapy will address these issues.

Our studies indicate that, according to the absence or presence of cytokines, HSC gene transfer can be tuned to limit the average level of vector integration, and reduce the risk of insertional mutagenesis, or instead to maximize transduction and transgene expression levels. Because LV integration preferentially targets active genes, cytokine stimulation may also affect the integration sites spectrum, making less or more likely that cytokine-responsive, growth-related genes are targeted.

Cytokines enhancement of SRC transduction was not linked to cell progression into S-phase, because it was not abrogated by treating the cells with the S-phase poison Ara-C after transduction.
Ara-C treated cells, both stimulated with cytokines and unstimulated, yielded lower, although not statistically significant, levels of human engraftment and transduction in transplanted mice. This suggests that a fraction of SRCs may become sensitive to Ara-C in vivo and that cells in this fraction are more permissive to LV. These more permissive cells may be those exiting from quiescence; because of an earlier S-phase induction upon transplantation, they may become sensitive to the delayed effect of Ara-C in vivo. The cells less susceptible to LV may be the quiescent cells; because of a delayed S-phase induction upon transplantation, they may be resistant to Ara-C. Because the SRCs successfully engrafting after Ara-C treatment were transduced to substantial levels, these findings strongly suggest that LVs are able to transduce quiescent SRCs. In this respect, HSCs may behave differently than lymphocytes that restrict LV transduction, and HIV-1 infection, in the G0 phase of the cell cycle.

In recent studies, restriction of retroviral and lentiviral infection has been ascribed to different families of cytosolic proteins that target viral uncoating or edit the viral genome and inhibit viral replication (reviewed in Goff23). Factors interfering with viral uncoating, such as TRIM5α, are typically identified by saturating their activity with increasing viral input. We could not overcome the relative resistance of unstimulated, as compared to cytokine-stimulated, cells by increasing the vector input. Rather than being dependent on cell cycle progression, or the elimination of a cytosolic restriction factor, the enhancement of LV transduction by cytokines in HSPCs may involve, at least in part, down-regulation of the proteasome activity. By directly testing the proteasome activities in stimulated and unstimulated HSPCs, we showed that they were significantly down-regulated by exposure to the cytokines. Importantly, this cytokines response was rapid, with a maximal effect at early time points corresponding to the period in which the first steps of LV transduction take place. Although it is difficult to estimate the actual level of inhibition reached in cells treated with MG132, the activity recovered after 24 hour exposure was similar to that recovered from cells exposed for 6 hours to cytokines, suggesting that the extent of down-regulation induced by the latter was substantial. However, because cytokine treatment further
enhanced transduction in drug-treated cells, it is likely that other mechanisms are also involved in increasing cell permissiveness to LV.

The down-regulation of proteasome activity in HSPCs in response to cytokines stimulation is a novel and intriguing finding, as it likely affects several cellular functions. Interestingly, SCF, TPO, and Flt3L all had an additive effect on the proteasome activity. Further studies will identify the signalling pathway from the cytokine receptors to the proteasome.

Direct measurement of integrated vector copy numbers in CD34+ cells and in SRCs transduced in the presence and absence of proteasome inhibitors showed a dramatic increase in transduction of cells exposed to the drugs. This indicates that a large excess of vector particles is uptaken but does not become integrated, and that the proteasome effectively restricts LV transduction in HSPCs. The mechanism of restriction still needs to be elucidated; the proteasome could act directly and target the uncoating vector core, most likely after it has been labeled for degradation by specific ubiquitin-conjugation systems, possibly recruited by restrictive factors; the proteasome could also act indirectly, by targeting factors required for the early steps of transduction.

Since we obtained a very high vector copy number in SRCs transduced with cytokines and proteasome inhibitor, further studies are needed to assess the impact on the target cell genome and evaluate the possible consequences of the increased insertional mutagenesis. However, as shown in Figure 3, using proteasome inhibitors in absence of cytokine stimulation allows reaching high-frequency transduction without necessarily increasing the average vector copy number to extremely high levels, thus providing a possible new strategy to optimize gene transfer. It is conceivable that both minimal and maximal thresholds of vector copy numbers providing the best risk-benefit ratio will have to be set according to each proposed gene therapy application.

Whereas proteasome inhibition increased LV transduction to some extent in several cell lines, effective proteasome restriction appeared to be a specific feature of HSPCs (this study) and lymphocytes. We correlated effective restriction with the high proteasome activity observed in
HSPCs. Two recent works\(^{46,47}\) reported increased HIV infection of some cell lines by proteasome inhibition, although the cells were scored 2 days after infection, thus without ruling out transient effects of the treatment on reporter expression.

In conclusion, we report a substantial increase in SRC gene transfer in the presence of proteasome inhibitor, and, importantly, no apparent adverse effect on the cell engraftment capacity. Further studies will determine the safety and efficacy of this approach to improve HSC gene therapy.
ACKNOWLEDGMENTS

We are grateful to S. Cenci, R. Sitia, M. De Palma, A. Thrasher and C. Di Serio for fruitful advice, F. Benedicenti and L. Sergi for technical help, A. Palini for help with FACS analysis, A. Ferrari and the San Raffaele Obstetric Department for CB collection, F.L Cosset, A. Stornaiuolo and B. Piovani for reagents.
REFERENCES


22


18. Unutmaz D, KewalRamani VN, Marmon S, Littman DR. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J.Exp.Med. 1999;189:1735-1746


### TABLES

#### Table 1. Competitive Repopulation Assay. SRCs analysis

<table>
<thead>
<tr>
<th>Reference Mice</th>
<th>Competitively Repopulated Mice</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GFP + cyt</strong></td>
<td></td>
</tr>
<tr>
<td>Mouse</td>
<td>%hCD45&lt;sup&gt;A&lt;/sup&gt;</td>
</tr>
<tr>
<td>1</td>
<td>45</td>
</tr>
<tr>
<td>2</td>
<td>41</td>
</tr>
<tr>
<td>3</td>
<td>64</td>
</tr>
<tr>
<td>4</td>
<td>16</td>
</tr>
<tr>
<td>Average</td>
<td>41</td>
</tr>
<tr>
<td><strong>GFP – cyt</strong></td>
<td></td>
</tr>
<tr>
<td>Mouse</td>
<td>%hCD45</td>
</tr>
<tr>
<td>1</td>
<td>66</td>
</tr>
<tr>
<td>2</td>
<td>53</td>
</tr>
<tr>
<td>3</td>
<td>17</td>
</tr>
<tr>
<td>4</td>
<td>18</td>
</tr>
<tr>
<td>5</td>
<td>20</td>
</tr>
<tr>
<td>6</td>
<td>59</td>
</tr>
<tr>
<td>Average</td>
<td>39</td>
</tr>
<tr>
<td><strong>YFP + cyt</strong></td>
<td></td>
</tr>
<tr>
<td>Mouse</td>
<td>%hCD45</td>
</tr>
<tr>
<td>1</td>
<td>40</td>
</tr>
<tr>
<td>2</td>
<td>24</td>
</tr>
<tr>
<td>3</td>
<td>50</td>
</tr>
<tr>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>50</td>
</tr>
<tr>
<td>Average</td>
<td>33</td>
</tr>
<tr>
<td><strong>YFP – cyt</strong></td>
<td></td>
</tr>
<tr>
<td>Mouse</td>
<td>%hCD45</td>
</tr>
<tr>
<td>1</td>
<td>45</td>
</tr>
<tr>
<td>2</td>
<td>15</td>
</tr>
<tr>
<td>3</td>
<td>60</td>
</tr>
<tr>
<td>4</td>
<td>19</td>
</tr>
<tr>
<td>5</td>
<td>11</td>
</tr>
<tr>
<td>Average</td>
<td>30</td>
</tr>
</tbody>
</table>

<sup>A</sup> percentage of human cells in the mouse BM  
<sup>B</sup> percentage of human cells expressing the indicated transgene
### Table 2. S-phase Suicide Assay. SRCs analysis

<table>
<thead>
<tr>
<th></th>
<th>FACS Analysis</th>
<th>CFC Assay</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%hCD45&lt;sup&gt;A&lt;/sup&gt;</td>
<td>%GFP&lt;sup&gt;B&lt;/sup&gt;</td>
</tr>
<tr>
<td>–cyt (n=4)</td>
<td>28±14</td>
<td>54±20</td>
</tr>
<tr>
<td>+cyt (n=4)</td>
<td>42±32</td>
<td>91±5</td>
</tr>
<tr>
<td>–cyt Ara-C (n=6)</td>
<td>23±22</td>
<td>29±8</td>
</tr>
<tr>
<td>+cyt Ara-C (n=5)</td>
<td>7±6</td>
<td>61±22</td>
</tr>
</tbody>
</table>

All values are expressed as mean±SD of two experiments performed.

<sup>A</sup> percentage of human cells in the mouse BM

<sup>B</sup> percentage of human GFP expressing cells

<sup>C</sup> p-value calculated by rank sum two-sided test

<sup>D</sup> percentage of human GFP expressing cells, scored by fluorescence microscopy

n: number of mice per group
FIGURE LEGENDS

Figure 1. Representative FACS Analysis of Competitively Repopulated NOD/SCID Mice.

Three-channels FACS analysis of mouse BM ten weeks after transplant of human CD34+ cells transduced with either LV-GFP or LV-YFP. A) Frequency of transgene expression in the human cell (hCD45+) graft. FACS plots from a competitively repopulated mouse, showing both GFP and YFP-positive cells (upper panels), and two reference mice, showing either YFP or GFP-positive cells (middle and lower panels), as indicated. Percentages of transgene-positive cells detected in each channel (FL-2: YFP; FL-1: GFP + YFP, FL-3: human CD45) are given in the respective quadrant. B) and C) Multilineage engraftment by transduced SRCs. Percentages shown represent the fraction of transgene-expressing cells among the indicated lineage marker-positive cells (scored in the FL-3 channel). Because both GFP and YFP signals emit in the FL-1 channel, we calculated the frequency of GFP-expressing cells by subtracting the fraction of YFP-expressing cells, scored in FL-2, from the percentage of cells scored positive in FL-1. Mouse numbers as in Table 1.

Figure 2. S-phase suicide assay of HSPCs assayed in vitro.

Human CD34+ cells were stimulated (+cyt) or not with cytokines (-cyt) for 18 hrs, exposed or not to Ara-C for further 12 hrs, as indicated, and analyzed immediately (A) or after 1 (B) or 2 (C) weeks of culture. For B and C, the cells were also transduced with LV-GFP during the first 18 hrs incubation. A) Cell cycle analysis. Upper panels, FACS histograms of Propidium Iodide (PI) staining. Lower panel, distribution of the analyzed cell populations in the indicated cell cycle phases, marked as M1 to 4 in the histogram. Apopt./Necr.: apoptotic/necrotic cells. B) Representative FACS analysis of GFP expression in suspension culture. Percentages of GFP-positive cells are given. C) CFC assay. GFP+ colonies were scored by fluorescence microscopy; CFC total number is expressed as number of colonies per 10^3 CD34+ cells plated; percentage of killing is calculated as the ratio between the number of colonies arising from the Ara-C treated and untreated populations. Average values of two experiments.
Figure 3. Effect of proteasome inhibition on HSPCs transduction by LV.

A) and C) Percentage of GFP+ cells, and B) and D) Mean Fluorescence Intensity (MFI) of CD34+ cells transduced with $10^8$ TU/ml of LV-GFP with (triangles) or without (squares) cytokines stimulation in the presence of increasing doses of the proteasome inhibitors MG132 (A and B) and PS-341 (C and D), and analyzed two weeks after transduction. Average of two experiments per panel. E) Percentages of GFP-positive cells in suspension culture (upper panel) and GFP-positive colonies from CFC assays (lower panel) from CD34+ cells transduced with or without cytokines (Cyt) stimulation with increasing doses of LV-GFP (TU/ml), and in the absence or presence of 1μM MG132 (MG), as indicated, and analyzed two weeks after. Toxicity was calculated from the ratio between the number of colonies arising from MG132-exposed and not exposed cells and shown as percentage of CFC killed. Average (——) and individual values (triangles and squares) from two experiments. Statistical analysis reported in the Results section. F) Quantitative real time PCR analysis of DNA extracted after 3 weeks of suspension culture from HSPCs stimulated or not with cytokines (Cyt), transduced with different doses of LV-GFP (TU/ml) and treated or not with different doses of PS341 (PS) or MG132 (MG), as indicated. Vector sequences were amplified with a system annealing to the $\psi$ of the vector (PSI system) and a system annealing to the GFP sequence (GFP system). For each condition average of three detections is shown.

Figure 4. Contribution of individual cytokines to enhanced HSPCs transduction by LV.

A) Percentage of GFP+ cells in suspension culture and colonies (CFC) of CD34+ cells transduced with $10^8$ TU/ml of LV-GFP without (-cyt) or with the indicated cytokine, added separately (IL6, SCF, TPO, Flt3L) or all together (+cyt), and with or without (NT, not treated) 1μM MG132. B) Mean Fluorescence Intensity (MFI) of suspension culture cells shown in A. One experiment of two performed with similar results is shown.
Figure 5. Proteasome activities in HSPCs cells.

CD34+ cells were treated as indicated, lysed and tested for proteasome peptidase activities. Peptidase activities were assayed by monitoring the production of 7-amino-4-methylcoumarin (amc) from fluorogenic peptides: Suc-LLVY-amc for the chymotrypsin-like activity, Boc-LRR-amc for the trypsin-like activity and Ac-YVAD-amc for the caspase-like activity. A) Peptidase activities of cells exposed to cytokines (+cyt) or not (-cyt) for 24 hours. B-D) Chymotripsin-like activity of cells kept in culture for the indicated times with (+cyt) or without (-cyt) cytokines (B); exposed to cytokines (+cyt), to MG132 (MG132), or to both treatments (+cyt MG132) for 24 hours (C); exposed to the indicated cytokine for 24 hours (D). Values in A-C are mean±SD of 3 measurements from one of two experiments with similar results, performed with different cell preparations. Values in D are the average of two experiments, and are expressed as percentage of the proteasome activity of unstimulated cells.

Figure 6. Effect of proteasome inhibition on LV transduction of different cell lines.

A) Frequency of GFP+ cells and B) MFI of 293T, HeLa, U937 and K562 cells transduced with LV-GFP in presence of increasing concentrations (from 0.1 to 2 μM) of MG132 for 12 hours. Missing points at the highest doses in K562 and U937 curves are due to cell death because of MG132 toxicity. Two to three experiments are shown for each cell line. C) CD34+ cells exposed (+cyt) or not (-cyt) to cytokines for 20-24 hours, HeLa, 293T, U937 and K562 cells were lysed and tested for proteasome chymotrypsin-like activity. Chymotrypsin-like activity was assayed by monitoring the production of 7-amino-4-methylcoumarin (amc) from fluorogenic peptide Suc-LLVY-amc. Values are mean±SD of 3 measurements from one of two experiments with similar results.

Figure 7. Effect of proteasome inhibition on SRC transduction.

CD34+ cells were transduced with LV-GFP without any stimulation (-cyt), in the presence of 0.7μM MG132 (-cyt MG), in the presence of cytokines (+cyt) or in the presence of both cytokines
and 0.7μM MG132 (+cyt MG), and transplanted in NOD/SCID mice. Mice BM was analysed 6 weeks after transplant by FACS (A) or by quantitative real time PCR (B and C). A) Percentage of GFP-positive cells in the human graft. B) Number of LV integrated copies per human cell. C) Percentage of human engraftment, calculated as ratio between human and total (human+murine) DNA. Each dot represents a mouse, for each group the average (―) is shown. D) FACS analysis of a mouse transplanted with cells transduced in presence of cytokines and MG132 and carrying 34 LV copies per cell; multi-lineage repopulation is shown by a similar percentage of GFP+ cells in all the indicated lineages. Percentages were calculated within the gated populations. Human engraftment level was 15%.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction

Francesca R Santoni de Sio, Paolo Cascio, Anna Zingale, Mauro Gasparini and Luigi Naldini